



The American College of  
Obstetricians and Gynecologists  
WOMEN'S HEALTH CARE PHYSICIANS

# ACOG PRACTICE BULLETIN

Clinical Management Guidelines for Obstetrician–Gynecologists

NUMBER 206

**Committee on Practice Bulletins—Gynecology.** This Practice Bulletin was developed by the Committee on Practice Bulletins—Gynecology in collaboration with Rebecca H. Allen, MD, MPH; Andrew Kaunitz, MD; and Deborah Bartz, MD, MPH.

## Use of Hormonal Contraception in Women With Coexisting Medical Conditions

*Although numerous studies have addressed the safety and effectiveness of hormonal contraceptive use in healthy women, data regarding women with underlying medical conditions or other special circumstances are limited. The U.S. Medical Eligibility Criteria (USMEC) for Contraceptive Use, 2016 (1), which has been endorsed by the American College of Obstetricians and Gynecologists, is a published guideline based on the best available evidence and expert opinion to help health care providers better care for women with chronic medical problems who need contraception. The goal of this Practice Bulletin is to explain how to use the USMEC rating system in clinical practice and to specifically discuss the rationale behind the ratings for various medical conditions. Contraception for women with human immunodeficiency virus (HIV) (2); the use of emergency contraception in women with medical coexisting medical conditions, including obesity, (3); and the effect of depot medroxyprogesterone acetate (DMPA) on bone health (4) are addressed in other documents from the American College of Obstetricians and Gynecologists.*

### Background

Decisions regarding contraception for women with coexisting medical conditions are critical. Hypertension, ischemic cardiac disease, valvular cardiac disease, diabetes, and stroke are a few conditions associated with increased risk of adverse outcomes in the setting of an unintended pregnancy (1). Medications taken for certain chronic conditions may be teratogenic or alter the effectiveness of hormonal contraception. Therefore, pregnancy planning is vital for the health of these patients to optimize their medical conditions before pregnancy (5) in order to improve maternal and neonatal outcomes (6).

Counseling women with coexisting medical conditions regarding contraception should balance the potential risks of using contraceptive methods against the potential risks of an unintended pregnancy. This will necessarily involve assessing the nature and severity of the patient's medical condition; the patient's personal

preferences; her reproductive goals; and the effectiveness, acceptability, and availability of alternative methods. Combined estrogen–progestin hormonal contraceptives include pill, vaginal ring, and patch formulations. Available progestin-only methods include DMPA injections, etonogestrel implant, progestin-only pills, and levonorgestrel-releasing intrauterine devices (LNG-IUDs). Practitioners should recognize that effective nonhormonal forms of contraception, such as the copper IUD or sterilization, remain safe choices for many women with medical conditions (1).

### Use of the U.S. Medical Eligibility Criteria for Contraceptive Use

The USMEC is routinely updated and uses four categories to classify medical conditions that affect eligibility for the use of each contraceptive method (Box 1). The four-tiered category system designates the level of risk associated with a particular contraceptive among women



with certain characteristics (eg, age or history of pregnancy) or known preexisting medical problems (eg, diabetes or hypertension) compared with the risk associated with unintended pregnancy (1). Unintended pregnancy and its associated risks, as opposed to no risk, is the comparative condition because approximately 85% of sexually active women will become pregnant within 1 year if they are not using contraceptives (7). When using hormonal contraceptives to treat gynecologic problems in conjunction with pregnancy prevention, the risk–benefit balance may change.

The USMEC category 1 indicates that there are no restrictions to use of the contraceptive. Category 2 indicates that the benefits of the contraceptive outweigh the risks and the patient still can use the method, although in certain situations there may be a need for additional follow-up. Category 3 means that the risks of the contraceptive generally outweigh the benefits. Nevertheless, the method still may be used if nothing else is available or acceptable to the patient and she has been counseled about the potential risks. The patient may require close follow-up to ensure that continued use is safe. Category 4 conveys that the method is contraindicated and should not be used (Box 1). Rarely, a Category 4 method might be considered and used in consultation with the patient's other health care providers if no alternative methods are available. In addition, certain USMEC recommendations are subdivided into two categories: 1) initiation (I) of a new contraceptive method and 2) continuation (C) of a currently used contraceptive method. The USMEC category for continuation should

guide decision making when a condition develops or worsens during use of a contraceptive method.

The USMEC recommendations assume that no other risk factors or conditions are present. When patients present with multiple medical conditions, the condition with the highest category number generally should be used to determine the safety of the contraceptive choice. For example, combined hormonal contraceptives for a 25-year-old woman with migraines with aura (USMEC category 4) and rheumatoid arthritis (USMEC category 2) would be contraindicated because of the migraines with aura. The USMEC does have one category that provides recommendations for the patient with multiple conditions: multiple risk factors for atherosclerotic cardiovascular disease (eg, older age, smoking, diabetes, hypertension, low high-density lipoprotein [HDL], high low-density lipoprotein [LDL], or high triglyceride levels).

## Clinical Considerations and Recommendations

### ► *Is hormonal contraception safe for women with a history of venous thromboembolism or at risk of a thromboembolic event?*

The estrogenic component of combined hormonal contraceptives increases hepatic production of serum globulins involved in coagulation (including factor VII, factor X, and fibrinogen) and increases the risk of venous thromboembolism (VTE) in users. Although all combined hormonal contraceptives cause an increased risk of VTE, this risk remains half as high as the elevated risk observed in pregnancy (8–10). Women with certain conditions associated with VTE (Box 2) should be counseled for nonhormonal or progestin-only contraceptives (1). For women with a prior VTE, the risk of a recurrent VTE depends on whether the initial thrombosis was associated with a risk factor that is permanent (eg, factor V Leiden) or reversible (eg, surgery) (11). Therefore, a combined hormonal contraceptive candidate with a history of a single episode of VTE that occurred years earlier and was associated with a nonrecurring risk factor (eg, after immobilization because of a motor vehicle accident) may not currently be at increased risk of a recurrent VTE, and a combined hormonal contraceptive may be considered if no other method is available or desired (USMEC category 3). Women at risk of VTE who use anticoagulation are at risk of gynecologic complications of this therapy, such as hemorrhagic ovarian cysts or heavy menstrual bleeding. Combined hormonal methods may be of benefit to these patients beyond pregnancy prevention, affecting the risk–benefit ratio for each patient and should be considered on a case-by-case basis.

### Box 1. Categories for Medical Eligibility Criteria for Contraceptive Use

1=A condition for which there is no restriction for the use of the contraceptive method.

2=A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.

3=A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.

4=A condition that represents an unacceptable health risk if the contraceptive method is used.

Reprinted from Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. *MMWR Recomm Rep* 2016;65(RR-3):1–104.



## Box 2. Risk Factors for Venous Thromboembolism in Users of Combined Hormonal Contraceptives\*

- Smoking and age 35 years or older
- Less than 21 days after giving birth or 21–42 days after giving birth with other risk factors (eg, age 35 years or older, previous venous thromboembolism, thrombophilia, immobility, transfusion at delivery, peripartum cardiomyopathy, body mass index of 30 or greater, postpartum hemorrhage, postcesarean delivery, preeclampsia, or smoking)
- Major surgery with prolonged immobilization
- History of deep vein thrombosis or pulmonary embolism
- Hereditary thrombophilia (including antiphospholipid syndrome)
- Inflammatory bowel disease with active or extensive disease, surgery, immobilization, corticosteroid use, vitamin deficiencies, or fluid depletion
- Systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies
- Superficial venous thrombosis (acute or history)

\*Combined hormonal contraceptive use in women with these conditions is classified as U.S. Medical Eligibility Criteria Category 3 (theoretical or proven risks usually outweigh the advantages of using the method) or Category 4 (condition that represents an unacceptable health risk if the contraceptive method is used).

Data from Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. *MMWR Recomm Rep* 2016;65(RR-3):1–104.

Venous thromboembolism with pulmonary embolism is a major cause of fatalities associated with surgical (including gynecologic) procedures (12). The normalization of clotting factors associated with stopping combined contraceptives is not observed unless discontinuation happens 4–6 weeks before major surgery (13). Health care providers should take into account the planned surgery and other risk factors the patient may have for VTE balanced against the risks of an unintended pregnancy (14–17). Use of combined hormonal contraceptives is contraindicated in patients undergoing major surgery with anticipated prolonged immobilization (USMEC category 4). Otherwise, if patients are expected to be ambulatory postoperatively, there is no reason to stop combined hormonal contraception (USMEC category 2).

Few studies have examined the safety of the combined hormonal contraceptive patch and ring in women with underlying medical conditions. The transdermal patch delivers total ethinyl estradiol serum concentrations that are higher than that seen in women who use oral contraceptive (OC) pills formulated with 30–35 micrograms ethinyl estradiol, although the peak ethinyl estradiol concentrations are lower than in women using such OCs (18, 19). Although the data are conflicting, the risk of VTE associated with the combined hormonal contraceptive patch and ring appears similar to that with combined OCs (20–22). Overall, contraindications to the use of combined OCs for VTE risk also should be considered to apply to the transdermal patch and the vaginal ring.

Studies of the estrogen dose of combined hormonal contraceptive pills have demonstrated that reductions in the ethinyl estradiol dose from 50 micrograms to less than 50 micrograms were associated with decreased risk of VTE (23). However, there is no strong evidence that a further reduction to 20 micrograms or 10 micrograms of ethinyl estradiol further reduces the VTE risk because published trials are not sufficiently large to definitively detect differences between the association of these estrogen doses (24, 25) or the type of estrogen (ethinyl estradiol versus estradiol valerate) (26) with rare adverse events such as VTE, myocardial infarction, and stroke (27, 28).

Combined hormonal contraceptives that contain older formulations of progestins (levonorgestrel and norethindrone) and newer progestins (desogestrel and drospirenone in oral contraception and etonogestrel in the vaginal ring) are associated with a comparable risk of VTE and can be recommended as equivalent options to women with a history of or at risk of VTE (9, 29–31). In evaluating this risk, several prospective cohort studies addressed important baseline confounders, including age, family history, and body mass index (BMI); categorized contraceptive users by duration of use; maintained regular contact with users; and individually validated each diagnosis of VTE (21, 32). These studies provide strong evidence that the risk of VTE associated with combined hormonal contraceptives formulated with desogestrel, drospirenone, and etonogestrel is similar to the risk associated with use of methods formulated with older progestins (4, 33).

Progestin-only pills, the contraceptive implant, or an LNG-IUD are appropriate options to initiate in women with a history of or at risk of VTE, myocardial infarction, or stroke (USMEC category 2) (34). However, the data for DMPA are less clear (34–36). A meta-analysis based on two studies found a twofold increased risk of VTE with progestin-only injectables (37). However, residual confounding from this analysis weakens the result (34, 38, 39). The USMEC allows the use of DMPA in women at risk of VTE (USMEC category 2).



The hypoestrogenic effect and increased total cholesterol levels seen in DMPA users (40, 41) result in concern that the risk might outweigh benefit of DMPA use in women with a personal history of ischemic heart disease or stroke (USMEC category 3). Although little concern exists about these effects with regard to progestin-only pills, the subdermal implant, and LNG-IUDs, these methods also become USMEC category 3 for method continuation if a new deep vein thrombosis, ischemic cardiac event, or stroke occur in women already using progestin-only pills, contraceptive implant, or an LNG-IUD. Contraceptive use in women who use anticoagulants because of their risk of VTE or for treatment of VTE is discussed in clinical question, *What hormonal contraceptive options are appropriate for women taking concomitant antiepileptic, antiretroviral, antimicrobial, or anticoagulation therapy?* later in this document.

► ***Is hormonal contraception safe for women with known thrombogenic mutations? Is routine screening for familial thrombophilias recommended before providing hormonal contraception?***

Use of combined hormonal contraceptives is contraindicated in women with known familial thrombophilias (USMEC category 4) (1). Progestin-only methods and LNG-IUDs are acceptable alternatives for individuals with known thrombogenic mutations (USMEC category 2). Women with thrombophilic syndromes, including factor V Leiden mutation, prothrombin G20210A mutation, protein C, protein S, or antithrombin deficiency have an increased risk of VTE during combined hormonal contraceptive use. They also may develop VTE more rapidly after initiation of combined hormonal contraceptive use than women without familial thrombophilias (42–44). In one study, women with heterozygous factor V Leiden mutation were found to have a baseline risk of VTE sevenfold higher than women without this mutation (45). The risk was more than 15–30 times higher in women heterozygous for the factor V Leiden mutation who used OCs than in women who used nonhormonal contraceptives and were not carriers of the mutation (45, 46).

Gynecologic care providers should not perform routine screening for familial thrombotic disorders before initiating combined hormonal contraceptives (1, 47). Screening would identify approximately 5% of U.S. OC candidates as having factor V Leiden mutation; however, most of these women will never experience VTE even if they used combined OCs (48). Given the rarity of fatal VTE, one group of investigators concluded that screening more than 1 million combined OC candidates for thrombophilic markers would, at best, prevent two OC-associated deaths (49). In addition, assessment of

methylenetetrahydrofolate reductase polymorphisms or measurement of fasting homocysteine levels is not recommended. Although hyperhomocysteinemia was previously believed to be a modest risk factor for VTE (50, 51), more recent data indicate that elevated homocysteine levels are a weak risk factor for VTE (52). And, methylenetetrahydrofolate reductase mutations by themselves do not appear to convey an increased risk of VTE (53).

► ***Are hormonal contraceptives safe for women with systemic lupus erythematosus?***

Patients with systemic lupus erythematosus (SLE) have an increased risk of arterial and venous thrombosis compared with the general population, with thrombosis being a major cause of death among SLE patients (54). Risk of thromboembolism is further increased by the presence of persistently positive antiphospholipid antibodies (55, 56). Furthermore, young women with SLE have an estimated 50-fold increased risk of myocardial infarction compared with age-matched and sex-matched controls (57). Accordingly, USMEC contraceptive recommendations are stratified according to the presence or absence of certain comorbidities: antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibody, and anti- $\beta_2$ -glycoprotein antibody), severe thrombocytopenia, and concomitant immunosuppressive medications (1). Women with SLE should be tested for antiphospholipid antibodies before initiating hormonal contraception (58–60). Combined hormonal contraception is contraindicated in women with SLE and positive antiphospholipid antibodies (USMEC category 4). In other SLE patients, use of combined hormonal contraceptive methods is rated USMEC category 2 in the absence of other cardiovascular disease risk factors (eg, older age, smoking, hypertension, diabetes, and hypercholesterolemia). Use of combined hormonal contraceptives does not appear to worsen SLE disease activity in women with inactive or stable active disease (61). Although progestin-only methods, including LNG-IUDs, are not considered to increase the risk of VTE, they are all rated USMEC category 3 for SLE patients with antiphospholipid antibodies. This is because the propensity for VTE is quite high in general in these patients (62). In SLE patients without antiphospholipid antibodies, progestin-only methods are rated USMEC category 2.

For women with SLE complicated by severe thrombocytopenia (less than 50,000 platelets/microliter), caution exists only for the initiation of DMPA (USMEC category 3). This is because of concerns for menstrual bleeding with severe thrombocytopenia that may be worsened by the irregular bleeding with the initiation of DMPA (1). Many women with SLE take immunosuppressant medications, and LNG-IUDs are demonstrated





to be safe without increased risk of infection, contraceptive failure, or other adverse events in immunosuppressed women (USMEC category 2) (62–66).

► ***Which hormonal contraceptives are appropriate for postpartum and breastfeeding women?***

Postpartum women should be offered contraception if rapid repeat pregnancy is not desired. Most nonbreastfeeding women will not ovulate until 6 weeks postpartum, however, some women may experience ovulation as early as 3 weeks postpartum (67). Pregnancy risk is decreased for 6 months at most in exclusively breastfeeding women who do not use formula supplementation and who, therefore, meet criteria for the lactational amenorrhea method of contraception.

### **Postpartum Venous Thromboembolism Risk**

Regardless of breastfeeding status, combined hormonal contraceptives are contraindicated during the first 21 days after giving birth because of the risk of VTE (USMEC category 4); therefore, health care providers should advise against initiating combined hormonal contraceptives during this time. Venous thromboembolism risk decreases postpartum day 21–42, although this risk continues to outweigh contraceptive benefits (USMEC category 3) in women with additional risk factors for VTE (Box 2) (1, 8, 68–73).

For women without other VTE risk factors, eligibility for use of combined hormonal contraceptives from postpartum day 21–30 is dependent upon breastfeeding status (Table 1). Beyond 30 days, women without VTE risk factors can use combined hormonal contraceptives regardless of breastfeeding status. The VTE risk does not return to baseline until 12 weeks postpartum, although the risk after 6 weeks is low (22.1 cases per 100,000 deliveries within 6 weeks versus 3.0 cases per 100,000 deliveries week 7 to week 12) (71).

### **Nonbreastfeeding Postpartum Women**

After 42 days in the postpartum period, there are no restrictions for combined hormonal contraceptives in nonbreastfeeding postpartum women. Progestin-only methods may be used without concern immediately after delivery in women who are not breastfeeding (USMEC category 1). Intrauterine devices are also an option either immediately after placental delivery or as an interval insertion at the postpartum visit (USMEC category 1). A peripartum course complicated by chorioamnionitis, postpartum endometritis, or sepsis makes IUD insertion contraindicated until evaluation by a clinician at the postpartum visit (USMEC category 4) (1, 74, 75).

### **Breastfeeding Postpartum Women**

Breastfeeding influences contraceptive options. Breastfeeding women may use progestin-only contraceptives at any time during the postpartum period and may use combined hormonal methods at 4–6 weeks after giving birth depending on VTE risk factors (76).

The benefits of progestin-only methods generally outweigh the risks in the first 30 days postpartum for breastfeeding women (USMEC category 2) (1, 74, 75). For breastfeeding women who are considering progestin-only methods, there is general agreement that progestin use after the onset of lactogenesis, generally in the first 48–72 hours postpartum, does not affect breastfeeding performance (77). There is a theoretical concern, nevertheless, that initiation of progestin methods immediately after giving birth could preempt lactogenesis given that progesterone withdrawal after delivery of the placenta is thought to be the trigger to prolactin secretion (78, 79). Nevertheless, although long-term data are limited, observational studies of progestin-only contraceptives suggest they have no effect on successful initiation and continuation of breastfeeding or on infant growth and development even when started immediately after giving birth (80).

Data regarding the effect of combined hormonal contraceptives on breastfeeding duration and infant outcomes are limited and inconsistent, with two recent systematic reviews unable to draw firm conclusions (78, 81). On an individual level, some women might be at risk of breastfeeding difficulties, and patient counseling regarding these concerns is warranted. Regardless of VTE risk, the use of combined hormonal contraceptives in breastfeeding women in the first 30 days after giving birth is to be avoided (USMEC category 4 through postpartum day 21 and category 3 through postpartum day 30). After 30 days, combined hormonal contraceptive use is USMEC category 2 for breastfeeding women because the benefits of contraception likely outweigh the theoretical effects on milk supply.

► ***Which hormonal contraceptives are appropriate for women of older reproductive age (age 40 years and older)? At what age can women stop the use of hormonal contraception?***

Healthy, nonsmoking women without specific risk factors for cardiovascular disease can continue combined hormonal contraception until age 50–55 years (USMEC category 2) (1, 24). There are no contraindications to the use of hormonal contraceptives on the basis of age alone, although age is an important risk factor for many chronic medical conditions, including cardiovascular disease (1).



**Table 1. U.S. Medical Eligibility Criteria for Postpartum Initiation of Hormonal Contraception\***

Contraceptive Type	Timing of Initiation	
	Breastfeeding	Not Breastfeeding
Combined hormonal contraceptives	During the first 21 days after giving birth (USMEC 4)  21–29 days after giving birth, regardless of VTE risk (USMEC 3)  30–42 days after giving birth: <ul style="list-style-type: none"> <li>• With other risk factors for VTE (USMEC 3)</li> <li>• Without other risk factors for VTE (USMEC 2)</li> </ul> More than 42 days after giving birth (USMEC 2)	During the first 21 days after giving birth (USMEC 4)  21–42 days after giving birth: <ul style="list-style-type: none"> <li>• With other risk factors for VTE (USMEC 3)</li> <li>• Without other risk factors for VTE (USMEC 2)</li> </ul> More than 42 days after giving birth (USMEC 1)
Progestin-only (implants, injectable DMPA, pills)	Less than 30 days after giving birth, regardless of VTE risk (USMEC 2)  30–42 days after giving birth, regardless of VTE risk (USMEC 1)  More than 42 days after giving birth (USMEC 1)	Any time, including immediately after giving birth (USMEC 1)
IUD-levonorgestrel	Immediately after placental delivery <sup>†</sup> , unless contraindications exist <sup>‡</sup> (USMEC 2)  Up to 4 weeks after giving birth, unless contraindications exist <sup>‡</sup> (USMEC 2)  At 4 or more weeks after giving birth (USMEC 1)	Immediately after placental delivery <sup>†</sup> , unless contraindications exist <sup>‡</sup> (USMEC 1)  Up to 4 weeks after giving birth, unless contraindications exist <sup>‡</sup> (USMEC 2)  At 4 or more weeks after giving birth (USMEC 1)

Abbreviations: DMPA, depot medroxyprogesterone acetate; IUD, intrauterine device; USMEC, U.S. Medical Eligibility Criteria; VTE, venous thromboembolism.

\*Before initiation of contraception, the obstetrician–gynecologist or other gynecologic care provider should be reasonably certain that the patient is not pregnant with a new pregnancy.

<sup>†</sup>Within 10 minutes after placental delivery in vaginal and cesarean births.

<sup>‡</sup>Immediate postpartum IUD insertion is contraindicated for women in whom uterine infection (ie, peripartum chorioamnionitis, endometritis, or puerperal sepsis) or ongoing postpartum hemorrhage are diagnosed (USMEC category 4).

Data from Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. *MMWR Recomm Rep* 2016;65(RR-3):1–104.

When deciding to stop use of a contraceptive method, the contraceptive and noncontraceptive benefits and the risks of the method must be evaluated in the context of the diminishing risk of pregnancy as the woman ages. It is estimated that the sterility rate is 17% at age 40, 55% by age 45, and 92% by age 50 (82). Routine assessment of follicle-stimulating hormone levels to determine when hormonal contraceptive users have become menopausal and, thus, no

longer need contraception may be misleading and is not recommended.

Perimenopausal women may benefit from the positive effect on bone mineral density (83), abnormal uterine bleeding (AUB) (84), and a reduction in vasomotor symptoms (85) offered by combined hormonal contraceptives. In addition, hormonal contraceptive use is associated with a reduced risk of endometrial cancer and ovarian cancer (86), which is of particular importance



to older women of reproductive age and those at increased risk of these types of cancer. However, because age is an independent risk factor for cardiovascular disease and thromboembolism, caution should be used if women have additional risk factors such as smoking, obesity, diabetes, hypertension, or migraine headaches with aura (USMEC category 3–4) (24, 87). Progestin-only OCs, subdermal implant, and LNG-IUDs are options for older women with these cardiovascular risk factors (USMEC category 1–2). Use of a 52-mg LNG-IUD may be particularly effective for the management of perimenopausal bleeding (88, 89). In older women who have been using DMPA long term, it is unknown if bone mineral density levels return to baseline before entering menopause. For this reason, DMPA use is USMEC category 2 in women who are older than 45 years without other risk factors for cardiovascular disease.

► ***Which hormonal contraceptives are appropriate for women with obesity?***

Women of all weights can get pregnant and no methods of contraception are contraindicated in women with obesity (1, 90). Based on a 2016 Cochrane review, women with obesity can be offered all hormonal contraceptive method options with reassurance that the efficacy of hormonal contraception is not significantly affected by weight (91). This conclusion is supported by a prospective cohort study of 1,523 women that found that the overall risk of unintended pregnancy in women who used the combined hormonal pill, patch, or ring was not significantly different across BMI categories, with an overall range of 8.4–11.0% at 3 years of use (92). This study was not able to evaluate efficacy separately among pill, patch, and ring users. The ability to detect small differences in contraceptive efficacy between women at normal weight and women with obesity may be obscured by adherence issues with short-term methods (93).

Nonetheless, further research is needed to better understand how contraceptive efficacy may be affected by weight, particularly in women with BMIs in the class III category (40 or greater). Pharmacokinetic studies show that, compared with normal weight women, women with obesity require twice as long to reach steady state therapeutic levels of contraceptive steroids when starting the pill or after the hormone-free interval because of changes in clearance (94, 95). It is possible that continuous OC use or using a 30–35-microgram pill compared with a 20-microgram pill may be more effective in women with obesity (96). A large, prospective cohort study of more than 52,000 women reported a slight increase in failure rates of combined OCs in patients with a BMI greater than 35 (hazard ratio of 1.5, 1.3–1.8,

95% CI), adjusting for age, parity, and education (97). However, this difference disappeared when evaluating pill dosages according to a 24/4 regimen compared with a 21/7 regimen. Evidence that evaluated the effectiveness of the patch and vaginal ring among women with obesity is limited, but both provide more effective contraception than barrier methods alone in women with obesity (90, 98, 99).

Combined hormonal contraceptives are rated USMEC category 2 for women with obesity. Although obesity and use of combined hormonal contraceptives represent independent risk factors for VTE (87, 100, 101), the absolute risk of VTE with combined hormonal contraceptives in women with obesity still is less than the risk of VTE during pregnancy and the puerperium in women with obesity (102, 103). Although there is conflicting evidence of an increased risk of acute myocardial infarction or stroke in women with obesity who use combined hormonal contraceptive methods (104), the overall absolute risk of these events in reproductive-aged women is low (24).

Consideration should be given to progestin-only and LNG-IUD methods when counseling women with obesity regarding contraceptive choices, particularly among patients who are older than 35 years. Higher pregnancy rates have not been observed among women who are overweight or obese with use of the 150-mg intramuscular or 104-mg subcutaneous formulations of DMPA (105, 106) or the etonogestrel implant (107). No association has been found between baseline weight and weight gain among adult DMPA users compared with nonusers (108, 109), although the data are mixed for new weight gain in adolescent DMPA users who are obese at the time of DMPA initiation (109–112). Because all LNG-IUDs work locally on the uterus and do not rely on systemic drug levels, their efficacy is not affected by BMI (93). Because women with obesity experience an elevated risk of AUB and endometrial hyperplasia, use of the LNG-IUD or other progestin-containing contraception may provide additional benefit of endometrial stabilization and protection (113, 114).

Women who undergo bariatric surgery that may compromise the absorption of oral medications (Roux-en-Y gastric bypass or biliopancreatic diversion) should not use oral contraception (combined hormonal or progestin-only) because efficacy may be impaired (USMEC category 3). Nonoral methods of contraception can be used without restriction (USMEC category 1) (115). There are no similar concerns for use of oral contraception in women who have had restrictive types of bariatric surgery (vertical banded gastroplasty, laparoscopic adjustable gastric band, or laparoscopic sleeve gastrectomy) (USMEC category 1).



► **What are the effects of hormonal contraception in women with depressed mood?**

Women with depressive disorders can use all methods of hormonal contraception (USMEC category 1) (1) because depressive symptoms do not appear to worsen with use of any method of hormonal contraception, including DMPA (116). Combined hormonal contraceptives use does not modify the effectiveness of fluoxetine (117). Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors do not appear to interact with the metabolism of hormonal contraceptives (117–119). In contrast, a clinical trial found that use of the herbal remedy St. John’s wort, a hepatic enzyme inducer that is commonly used as an over-the-counter treatment for depression, increased progestin and estrogen metabolism as well as breakthrough bleeding and the likelihood of ovulation in women using combined OCs

(120, 121). For this reason, concomitant use of St. John’s wort is rated USMEC category 2 for combined hormonal contraception, progestin-only pills, and the etonogestrel implant.

► **Is hormonal contraception safe for women with migraine headaches?**

Migraine without aura (Box 3) is the most common subtype of migraine, accounting for 75% of cases. Menstrual migraine is a subtype of migraine without aura that may be treated with extended use of hormonal contraception as a means of minimizing endogenous hormonal fluctuations (122). Aura is the complex of neurologic symptoms, usually visual, that occurs usually before the headache. Aura lasts 5–60 minutes and can present as zigzag lines spreading across the visual field, or sensory symptoms, such as pins and needles, speech disturbances, or motor weakness (123).

**Box 3. Diagnostic Criteria for Migraine With and Without Aura**

Migraine Without Aura	Migraine With Aura
<p>A. At least five lifetime attacks fulfilling criteria B–D</p> <p>B. Headache attacks lasting 4–72 hours (untreated or unsuccessfully treated)</p> <p>C. Headache has at least two of the following four characteristics:</p> <ol style="list-style-type: none"> <li>1. unilateral location</li> <li>2. pulsating quality</li> <li>3. moderate or severe pain intensity</li> <li>4. aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)</li> </ol> <p>D. During headache at least one of the following:</p> <ol style="list-style-type: none"> <li>1. nausea or vomiting, or both</li> <li>2. photophobia and phonophobia</li> </ol> <p>E. Not better accounted for by another ICHD-3 diagnosis.</p>	<p>A. At least two attacks fulfilling criteria B and C</p> <p>B. One or more of the following fully reversible aura symptoms:</p> <ol style="list-style-type: none"> <li>1. visual</li> <li>2. sensory</li> <li>3. speech and/or language</li> <li>4. motor</li> <li>5. brainstem</li> <li>6. retinal</li> </ol> <p>C. At least three of the following six characteristics:</p> <ol style="list-style-type: none"> <li>1. at least one aura symptom spreads gradually over <math>\geq 5</math> minutes</li> <li>2. two or more aura symptoms occur in succession</li> <li>3. each individual aura symptom lasts 5–60 minutes</li> <li>4. at least one aura symptom is unilateral</li> <li>5. at least one aura symptom is positive (ie, scintillations or pins and needles)</li> <li>6. the aura is accompanied, or followed within 60 minutes, by headache</li> </ol> <p>D. Not better accounted for by another ICHD-3 diagnosis</p>

Abbreviation: ICHD-3, *International Classification of Headache Disorders*, 3rd edition.

Data from *The International Classification of Headache Disorders*, 3rd edition. Headache Classification Committee of the International Headache Society (IHS) *Cephalalgia* 2018;38:1–211.





At the time of contraceptive initiation, the diagnosis of migraine with or without aura should be carefully considered in all women who present with a history of headache (Box 3). There are no contraindications to the use of any progestin-only method in women with migraines with or without aura (USMEC category 1) (1, 34, 124). Combined hormonal contraceptives can be used in women who have migraine without aura and no other risk factors for stroke (USMEC category 2). Estrogen-containing contraceptives are not recommended for women who have migraine with aura because of the increased risk of stroke (USMEC category 4) (124–127).

Although the absolute risk of ischemic stroke is low in women of reproductive age (128), migraine, particularly migraine with aura (129, 130), increasing age (131), and combined hormonal contraceptive use represent independent risk factors for stroke (132, 133). The risk of stroke among women using combined hormonal contraceptives rises with increasing age from 3.4 events per 100,000 women-years in adolescents to 64.4 events per 100,000 women-years among women aged 45–49 years (24). In a recent case-control study, investigators found that combined hormonal contraceptive use by women with migraines with aura synergistically increased the risk of stroke (134). In contrast, use of combined hormonal contraceptives by women with migraines without aura did not increase the risk over baseline. After adjusting for hypertension, diabetes, obesity, smoking, ischemic heart disease, and valvular heart disease, compared with women with *neither* migraine *nor* combined hormonal contraceptive use, the odds ratio (OR) of ischemic stroke was highest among women with migraine *with* aura *using* combined hormonal contraceptives (adjusted OR, 6.1; 95% CI, 3.1–12.1) and those with migraine *with* aura *not* using combined hormonal contraceptives (adjusted OR, 2.7; 95% CI, 1.9–3.7). In contrast, the risk of ischemic stroke was lower for women with migraine without aura using combined hormonal contraceptives (adjusted OR, 1.8; 95% CI, 1.1–2.9) and for women with migraine without aura not using combined hormonal contraceptives (adjusted OR, 2.2; 95% CI, 1.9–2.7) (134).

► ***Is the use of hormonal contraception safe for women with chronic hypertension?***

Women with blood pressure (BP) below 140/90 mm Hg may use any hormonal contraceptive method. In women with hypertension of systolic 140–159 mm Hg or diastolic 90–99 mm Hg, combined hormonal contraceptives should not be used unless no other method is appropriate for or acceptable to the patient (USMEC category 3). Women with hypertension of systolic 160 mm Hg or greater or diastolic 100 mm Hg or greater or with vascular

disease should not use combined hormonal contraceptives (USMEC category 4) (1).

The American College of Cardiology and the American Heart Association released a 2017 guideline that provides new BP standards and definitions: normal BP is defined as systolic less than 120 mm Hg and diastolic less than 80 mm Hg; elevated BP is systolic 120–129 mm Hg and diastolic less than 80 mm Hg; hypertension stage 1 is systolic 130–139 mm Hg or diastolic 80–89 mm Hg; and hypertension stage 2 is systolic 140 mm Hg or greater or diastolic 90 mm Hg or greater (135). Although the USMEC was created under previous definitions of hypertension, little data exist to help delineate risk of hormonal contraception in the new definition of hypertension stage 1 (systolic 130–139 mm Hg or diastolic 80–89 mm Hg) compared with women with BP systolic 140 mm Hg or greater or diastolic 90 mm Hg or greater. Therefore, obstetrician-gynecologists and other gynecologic care providers should continue to follow the current USMEC recommendations for women with elevated BP levels.

Although the absolute risk is low, it is estimated that among women using combined hormonal contraceptives, the relative risk of acute myocardial infarction in women with hypertension is increased by a factor of 12 compared with those who are not using combined hormonal contraceptives (136). With regard to contraceptive risk, hypertension USMEC classifications are based on assumptions that no other risk factors exist for cardiovascular disease. When multiple risk factors exist, combined hormonal contraception may increase a patient's cardiovascular disease risk to an unacceptable level (USMEC categories 3 and 4) (1).

Women on antihypertensive medication represent a separate category. Although the risk of cardiovascular disease in women with hypertension adequately controlled with medications should be reduced, there are no data on the use of combined hormonal contraceptives in this population. Therefore, use of combined hormonal contraceptives in these women is USMEC category 3 and requires clinical judgment regarding risk of pregnancy and patient acceptability of progestin-only or nonhormonal contraceptive methods. Women with well-controlled and monitored hypertension who are 35 years or younger may be appropriate candidates for a trial of combined hormonal contraceptives, provided they are otherwise healthy, show no evidence of end-organ vascular disease, and do not smoke cigarettes. If BP remains well controlled with careful monitoring several months after contraceptive initiation, use may be continued.

Contemporary low-dose (35 micrograms or less) combined estrogen-progestin OCs appear to increase BP



in a slight, likely nonclinically significant manner (137): approximately 8 mm Hg systolic and 6 mm Hg diastolic compared with no such increase in women beginning use of a copper IUD (138). Although few women develop overt hypertension after starting combined hormonal contraceptives, BP should be checked at follow-up visits and discontinuation of the hormonal method should be considered if BP increases significantly in the absence of other obvious causes (137, 139).

Use of progestin-only pills does not appear to have a significant effect on BP (140) or cardiovascular disease risk (141). Blood pressure measurement before or during the use of progestin-only pills, DMPA, subdermal implant, or LNG-IUD methods is not necessary (139). Unlike other progestins, the use of DMPA in women with hypertension of systolic 160 mm Hg or greater or diastolic 100 mm Hg or greater is generally not advised because of the theoretical risk of unfavorable lipoprotein changes that could contribute to cardiovascular risk (USMEC category 3) (1). However, the risks and benefits of the method need to be weighed against the risks of adverse pregnancy outcomes in women with hypertension.

► ***Is the use of hormonal contraception safe for women with diabetes?***

Available data offer reassurance that hormonal contraception does not affect carbohydrate metabolism in women without diabetes and, therefore, is unlikely to precipitate diabetes disease (142). For women with uncomplicated insulin or noninsulin dependent diabetes, no methods of hormonal contraception are contraindicated based on available data (USMEC category 2) (143). However, for women with diabetes of more than 20 years of duration or evidence of microvascular disease (retinopathy, nephropathy, or neuropathy), combined hormonal contraceptives are contraindicated (USMEC category 3 or 4 depending on the severity of the condition) (1). Because DMPA increases lipoprotein profiles favorable to atherosclerosis (40, 144), DMPA also is given a USMEC category 3 rating for women with diabetes of more than 20 years' duration or evidence of microvascular disease for fear of compounding already existing cardiovascular disease. The progestin-only pill, LNG-IUDs, and subdermal implant are suitable alternatives for this population.

► ***Is use of hormonal contraception appropriate for women at elevated risk of breast and ovarian cancer?***

Gynecologic care providers need not restrict use of any hormonal contraception in women with a family history

of breast cancer (USMEC category 1) or women with identified mutations in breast cancer susceptibility genes (eg, *BRCA1* and *BRCA2*) who have not personally been diagnosed with breast cancer (1, 145, 146). Women with a family history of breast cancer (often defined as having two or more close relatives with this malignancy) have a twofold to threefold elevated risk of breast cancer compared with women without such a family history (147). A systematic review identified 10 individual studies and one pooled analysis of 54 studies published between 1966 and 2008 that assessed risk of breast cancer with respect to combined hormonal contraceptive use and family history. Overall, this review concluded that use of OCs does not significantly affect risk of breast cancer in women with a family history of this disease (148). Similarly, in a 2013 systematic review and meta-analysis of *BRCA1* and *BRCA2* mutation carriers, OC use showed an increased but nonsignificant association with breast cancer (OR, 1.21; 95% CI, 0.93–1.58) and a significant inverse association with ovarian cancer (OR, 0.58; 95% CI, 0.46–0.73) (149). Studies also suggested stronger protection against ovarian cancer with longer duration of combined hormonal contraceptive use. Findings were similar when *BRCA1* and *BRCA2* mutations were examined separately (149, 150).

► ***What hormonal contraceptive options are appropriate for women with a history of breast or gynecologic cancer, including gestational trophoblastic disease?***

## **Breast Cancer**

Many cases of breast cancer are hormonally sensitive. Accordingly, there are theoretic concerns that use of combination estrogen–progestin or progestin-only contraception, including the LNG-IUD, may worsen the prognosis of women who have been treated for breast cancer (USMEC category 4 for current or recent breast cancer and category 3 for no evidence of disease for 5 years or more) (1, 151). Gynecologic care providers can recommend the use of the copper IUD as an appropriate contraceptive option for women who have been treated for breast cancer (USMEC category 1).

Commonly used to reduce recurrence risk in premenopausal breast cancer survivors, tamoxifen increases risk of endometrial polyps and AUB (152). Off-label use of the 52-mg LNG-IUD significantly reduces the risk of endometrial polyps in this setting (153). The effect of using LNG-IUDs on recurrence risk in breast cancer patients is uncertain. One study of 79 premenopausal breast cancer patients who used a 52-mg LNG-IUD and 120 patients who did not use this contraceptive found that,



overall, with a mean follow-up of 2.8 years, the recurrence rate was similar among survivors who did and did not use the LNG-IUD (154). However, among those women who were using the LNG-IUD at the time of breast cancer diagnosis and continued use of this IUD, risk of recurrence was elevated from 16.6% to 21.5%, with this higher risk achieving marginal statistical significance. One limitation of this observational study is the possibility that women who did not use the LNG-IUD may have used OCs or other hormonal methods of birth control. Decisions regarding use of LNG-IUDs in breast cancer survivors should balance the unknown risk of recurrence against its potential benefit on a case-by-case basis. Consultation with the patient's medical oncologist can be useful in these cases.

### **Gynecologic Cancer**

Screening for cervical cancer in patients without signs or symptoms should not be required before the provision of contraception (155). Women in whom cervical, endometrial, or ovarian cancer is diagnosed often have subsequent gynecologic surgery that obviates the need for contraception due to resulting surgical sterility. However, while a patient is awaiting surgical treatment or if sterility does not result from treatment of the gynecologic cancer, use of combined hormonal or progestin-only contraception, including continuation of a previously placed LNG-IUD, is appropriate (USMEC category 1 or 2) (1). For those patients with endometrial hyperplasia or malignancy who are not surgical candidates or who decline surgery, a progestin-based method, particularly DMPA and the 52-mg LNG-IUD, may be used (156, 157).

### **Gestational Trophoblastic Disease**

Chronic monitoring of human chorionic gonadotropin (hCG) levels represents a key component of care after women have been treated for gestational trophoblastic disease. Accordingly, effective contraception is important to minimize the risk of a new pregnancy that could confound the recovery from gestational trophoblastic disease. For women who have been treated for gestational trophoblastic disease with suction curettage, if hCG levels are falling or undetectable or if hCG levels are elevated but intrauterine disease is not evident or suspected, any hormonal method of contraception is considered appropriate (USMEC category 1 or 2) (1). However, because of concerns regarding possible bleeding, infection, or perforation, placement of a new IUD is not appropriate in women with gestational trophoblastic disease for whom there is persistently elevated hCG levels or malignant disease when intrauterine disease is evident or suspected (USMEC category 4) (158).

### **► What hormonal contraceptive options are appropriate for women taking concomitant antiepileptic, antiretroviral, antimicrobial, or anticoagulation therapy?**

Women taking rifampin and liver-enzyme inducing antiepileptic and antiretroviral medications that interfere with contraceptive steroid efficacy can use DMPA and LNG-IUDs without concern for increased contraceptive failure (USMEC category 1). Combined hormonal contraception or progestin-only pills generally are not recommended because of the increased risk of contraceptive failure (USMEC category 3). The efficacy of the etonogestrel implant also may be susceptible to medications that interfere with contraceptive steroids (USMEC category 2).

### **Antiepileptic Drugs**

Epilepsy represents a chronic condition that warrants effective contraception as part of the medical care plan because seizure activity worsens during pregnancy (159), negatively affecting maternal and fetal outcomes (160). Furthermore, fetal antiepileptic drug exposure is associated with a twofold to threefold increased risk of major congenital malformations compared with the general population, with even higher rates reported with valproate or polytherapy use (161).

Several antiepileptic drugs induce hepatic enzymes (Box 4), which can result in decreased serum concentrations of one or both of the estrogen or progestin components of hormonal contraceptives, putting women at risk of contraceptive failure and unintended pregnancy (162); accordingly, use of combined hormonal contraceptives in the setting of hepatic enzyme-inducing antiepileptic drugs is classified as USMEC category 3. Although studies demonstrate reduced serum levels of OC steroids during use of hepatic enzyme-inducing antiepileptic drugs and associated breakthrough ovulation (163, 164) or bleeding (163–167), investigators did not assess for accidental pregnancy during anticonvulsant use. If combined hormonal contraceptives are used in combination with antiepileptics that reduce steroid levels, combined hormonal contraceptive efficacy may be improved with formulations that contain 30–35 micrograms rather than lower doses of ethinyl estradiol (1), progestins known to have a longer half-life (drospirenone, desogestrel, levonorgestrel), and with hormone-free intervals shorter than 7 days to minimize the risk of escape ovulation (97, 168). Minimal data are available that examine the use of vaginal rings or transdermal patches with concomitant use of antiepileptic drugs. Serum norethindrone levels during use of progestin-only pills are lower than during use of combined OCs. Accordingly, use of progestin-only pills with antiepileptic drugs that induce





hepatic enzymes is rated USMEC category 3 because of the risk of pregnancy.

Depot medroxyprogesterone acetate and IUDs represent two preferred contraceptives for women taking liver enzyme-inducing antiepileptic drugs (USMEC category 1). Progestin levels are high with DMPA; 150 mg intramuscularly every 3 months represents a dose substantially higher than needed to suppress ovulation. Therefore, of all the systemic hormonal contraceptives, DMPA should be the method most likely to maintain contraceptive efficacy with concomitant use of liver enzyme-inducing anticonvulsants, though no pharmacodynamic studies are available to demonstrate this (168).

#### **Box 4. Classification of Antiepileptic Drugs**

##### **Liver Enzyme Inducers**

- Carbamazepine
- Felbamate
- Oxcarbazepine
- Phenobarbital
- Phenytoin
- Primidone
- Rufinamide

##### **Noninducers of Liver Enzymes**

- Clobazam
- Clonazepam
- Ethosuximide
- Ezogabine
- Gabapentin
- Lacosamide
- Lamotrigine\*
- Levetiracetam
- Pregabalin
- Tiagabine
- Topiramate†
- Valproate
- Vigabatrin
- Zonisamide

\*Lamotrigine does not affect levels of ethinyl estradiol. Although lamotrigine lowers C<sub>max</sub>, area under the curve, and trough levels of the progestin levonorgestrel, the changes are very small and unlikely to affect efficacy.

†Topiramate given at a dose of 200 mg a day does not affect levels of norethindrone. Topiramate decreases area under the curve and C<sub>max</sub>, but not trough levels, of ethinyl estradiol when given at a dose of 200 mg a day.

Adapted from Davis AR, Pack AM, Dennis A. Contraception for women with epilepsy. In: Allen RH, Cwiak CA, editors. Contraception for the medically challenging patient. New York (NY): Springer; 2014. p. 135–6.

The contraceptive efficacy of a 52-mg LNG-IUD has been observed to remain high with concomitant use of antiepileptic and other liver enzyme-inducing medications (169). A pharmacokinetic study indicates decreased serum levels of etonogestrel in women taking carbamazepine (170), and there are case reports of pregnancy occurring in women using the implant while taking enzyme-inducing antiepileptic medications (171, 172). However, because the etonogestrel implant is so effective at preventing pregnancy in general, the risk of contraceptive failure likely remains quite low in comparison with other contraceptive methods. This method is, therefore, rated USMEC category 2 for women on enzyme-inducing antiepileptic medications.

Lamotrigine is the only antiepileptic medication known to have its metabolism affected by estrogen-containing contraceptives, which reduces lamotrigine serum levels with concomitant use (173, 174). Therefore, dose adjustments of lamotrigine may be needed if hormonal contraceptives are used concomitantly and lamotrigine levels may increase during the hormone-free intervals.

#### **Antimicrobial and Antiretroviral Therapy**

Rifampin and rifabutin, two antimycobacterial drugs in the rifamycin class, appear to affect the metabolism of estrogen and progestin and have pharmacokinetic evidence of lower serum steroid levels, which may affect contraceptive efficacy (175–178). However, all other broad-spectrum antibiotics, antifungals, and antiparasitics do not interfere with OC efficacy (1, 178, 179). Theoretically, several antiretroviral medications may affect the metabolism of estrogen and progestin, although all but fosamprenavir can be taken with concomitant use of all hormonal birth control methods (USMEC category 1 or 2) (1, 2). Pharmacokinetic studies have not demonstrated decreased OC steroid levels with concomitant use of tetracycline, doxycycline, ampicillin, metronidazole, or quinolone antibiotics (180). A pharmacokinetic study noted that concomitant use of fluconazole does not decrease steroid levels in women who used combined OCs (181). Trials of women who used the contraceptive vaginal ring noted that contraceptive steroid levels were not reduced by ampicillin, doxycycline, or single or multiple administration of nonprescription vaginal miconazole suppositories or cream (182, 183). Data are limited but, theoretically, because broad-spectrum antibiotics do not affect efficacy of OC pills, it is likely that they also do not affect the efficacy of the contraceptive patch. One study demonstrated a short course of tetracycline did not affect the pharmacokinetics of norelgestromin or ethinyl





estradiol in patients who used the contraceptive patch (184).

The efficacy of progestin-only pills (USMEC category 3) and the etonogestrel subdermal implant (USMEC category 2) is likely to be decreased with concomitant use of rifampin. There is no evidence that the efficacy of DMPA or the LNG-IUD decreases with rifampin (185), and these contraceptives should be encouraged for women using rifampin or rifabutin long-term (USMEC category 1).

## Anticoagulants

All progestin-only methods are acceptable for women taking anticoagulants (USMEC category 2). Women using warfarin or other medications for chronic anticoagulation may experience heavy menstrual bleeding and, rarely, hemoperitoneum after rupture of ovarian cysts. In addition, warfarin is a teratogen and women on this medication should have access to reliable contraception. Methods studied to treat heavy menstrual bleeding induced by anticoagulation therapy include the 52-mg LNG-IUD and DMPA, with DMPA having the added benefit of preventing ovarian cyst formation and rupture (186). Evidence, although limited, has not revealed intramuscular DMPA injection site problems, such as hematoma in women taking anticoagulants (187). Because the 52-mg LNG-IUD provides effective contraception and significantly reduces menstrual blood loss, it is an excellent contraceptive method for patients taking anticoagulants (186, 188, 189). Use of combined hormonal contraceptives also can reduce menstrual blood loss (88, 190) but is associated with an increased risk of VTE. Because the risk of recurrent thrombosis is low in women on therapeutic anticoagulation, the use of combined contraceptives can be considered for such women on a case-by-case basis, especially if alternative methods are not acceptable to the woman or are contraindicated (USMEC category 3) (191).

## Summary of Recommendations

*The following recommendations are based on good and consistent scientific evidence (Level A):*

- ▶ Women with certain conditions associated with VTE should be counseled for nonhormonal or progestin-only contraceptives.
- ▶ Gynecologic care providers should not perform routine screening for familial thrombotic disorders before initiating combined hormonal contraceptives.
- ▶ Use of combined hormonal contraceptives is contraindicated in women with known familial thrombophilias (USMEC category 4). Progestin-only methods and LNG-IUDs are acceptable alternatives for individuals with known thrombogenic mutations (USMEC category 2).
- ▶ Women with SLE should be tested for antiphospholipid antibodies before initiating hormonal contraception. Combined hormonal contraception is contraindicated in women with SLE and positive antiphospholipid antibodies (USMEC category 4).
- ▶ Regardless of breastfeeding status, combined hormonal contraceptives are contraindicated during the first 21 days after giving birth because of the risk of VTE (USMEC category 4); therefore, health care providers should advise against initiating combined hormonal contraceptives during this time. Venous thromboembolism risk decreases postpartum day 21–42, although this risk continues to outweigh contraceptive benefits (USMEC category 3) in women with additional risk factors for VTE.
- ▶ At the time of contraceptive initiation, the diagnosis of migraine with or without aura should be carefully considered in all women who present with a history of headache.
- ▶ Combined hormonal contraceptives can be used in women who have migraine without aura and no other risk factors for stroke (USMEC category 2). Estrogen-containing contraceptives are not recommended for women who have migraine with aura because of the increased risk of stroke (USMEC category 4).
- ▶ Women with blood pressure below 140/90 mm Hg may use any hormonal contraceptive method. In women with hypertension of systolic 140–159 mm Hg or diastolic 90–99 mm Hg, combined hormonal contraceptives should not be used unless no other method is appropriate for or acceptable to the patient (USMEC category 3). Women with hypertension of systolic 160 mm Hg or greater or diastolic 100 mm Hg or greater or with vascular disease should not use combined hormonal contraceptives (USMEC category 4).
- ▶ For women with uncomplicated insulin or non-insulin dependent diabetes, no methods of hormonal contraception are contraindicated based on available data (USMEC category 2). However, for women with diabetes of more than 20 years of duration or evidence of microvascular disease (retinopathy, nephropathy, or neuropathy), combined hormonal contraceptives are contraindicated (USMEC category 3 or 4 depending on the severity of the condition).



***The following recommendations are based on limited or inconsistent scientific evidence (Level B):***

- ▶ Combined hormonal contraceptives that contain older formulations of progestins (levonorgestrel and norethindrone) and newer progestins (desogestrel and drospirenone in oral contraception and etonogestrel in the vaginal ring) are associated with a comparable risk of VTE and can be recommended as equivalent options to women with a history of or at risk of VTE.
- ▶ Progestin-only pills, the contraceptive implant, or an LNG-IUD are appropriate options to initiate in women with a history of or at risk of VTE, myocardial infarction, or stroke (USMEC category 2).
- ▶ Breastfeeding women may use progestin-only contraceptives at any time during the postpartum period and may use combined hormonal methods at 4–6 weeks after giving birth depending on VTE risk factors.
- ▶ Women with obesity can be offered all hormonal contraceptive method options with reassurance that the efficacy of hormonal contraception is not significantly affected by weight.
- ▶ Women with depressive disorders can use all methods of hormonal contraception (USMEC category 1) because depressive symptoms do not appear to worsen with use of any method of hormonal contraception, including DMPA.
- ▶ Gynecologic care providers need not restrict use of any hormonal contraception in women with a family history of breast cancer (USMEC category 1) or women with identified mutations in breast cancer susceptibility genes (eg, *BRCA1* and *BRCA2*) who have not personally been diagnosed with breast cancer.
- ▶ Women taking rifampin and liver-enzyme inducing antiepileptic and antiretroviral medications that interfere with contraceptive steroid efficacy can use DMPA and LNG-IUDs without concern for increased contraceptive failure (USMEC category 1). Combined hormonal contraception or progestin-only pills generally are not recommended because of the increased risk of contraceptive failure (USMEC category 3).

***The following recommendations are based primarily on consensus and expert opinion (Level C):***

- ▶ Healthy, nonsmoking women without specific risk factors for cardiovascular disease can continue combined hormonal contraception until age 50–55 years (USMEC category 2).
- ▶ Routine assessment of follicle-stimulating hormone levels to determine when hormonal contraceptive

users have become menopausal and, thus, no longer need contraception may be misleading and is not recommended.

- ▶ Women who undergo bariatric surgery that may compromise the absorption of oral medications (Roux-en-Y gastric bypass or biliopancreatic diversion) should not use oral contraception (combined hormonal or progestin-only) because efficacy may be impaired (USMEC category 3). Nonoral methods of contraception can be used without restriction (USMEC category 1).
- ▶ Gynecologic care providers can recommend the use of the copper IUD as an appropriate contraceptive option for women who have been treated for breast cancer (USMEC category 1).
- ▶ Decisions regarding use of LNG-IUDs in breast cancer survivors should balance the unknown risk of recurrence against its potential benefit on a case-by-case basis. Consultation with the patient's medical oncologist can be useful in these cases.

## References

1. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. *MMWR Recomm Rep* 2016; 65(RR-3):1–104. (Level III)
2. Gynecologic care for women and adolescents with human immunodeficiency virus. Practice Bulletin No. 167. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2016;128:e89–e110. (Level III)
3. Emergency contraception. Practice Bulletin No. 152. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2015;126:e1–11. (Level III)
4. Depot medroxyprogesterone acetate and bone effects. Committee Opinion No. 602. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2014;123: 1398–402. (Level III)
5. Champaloux SW, Tepper NK, Curtis KM, Zapata LB, Whiteman MK, Marchbanks PA, et al. Contraceptive use among women with medical conditions in a nationwide privately insured population. *Obstet Gynecol* 2015; 126:1151–9. (Level II-3)
6. Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-related mortality in the United States, 2011–2013. *Obstet Gynecol* 2017;130:366–73. (Level II-3)
7. Thoma ME, McLain AC, Louis JF, King RB, Trumble AC, Sundaram R, et al. Prevalence of infertility in the United States as estimated by the current duration approach and a traditional constructed approach. *Fertil Steril* 2013;99:1324–31.e1. (Level II-3)
8. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum:



- a 30-year population-based study. *Ann Intern Med* 2005;143:697–706. (Level II-3)
9. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. *Contraception* 2007;75:344–54. (Level II-2)
  10. Venous thromboembolism in women: a specific reproductive health risk. ESHRE Capri Workshop Group. *Hum Reprod Update* 2013;19:471–82. (Level III)
  11. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. *Lancet* 2003;362:523–6. (Level II-2)
  12. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. *Thromb Haemost* 2003;90:446–55. (Level II-3)
  13. Robinson GE, Burren T, Mackie IJ, Bounds W, Walshe K, Faint R, et al. Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery. *BMJ* 1991;302:269–71. (Level II-3)
  14. Prevention of deep vein thrombosis and pulmonary embolism. ACOG Practice Bulletin No. 84. American College of Obstetricians and Gynecologists [published erratum appears in *Obstet Gynecol* 2016;127:166]. *Obstet Gynecol* 2007;110:429–40. (Level III)
  15. Clarke-Pearson DL, Abaid LN. Prevention of venous thromboembolic events after gynecologic surgery [published erratum appears in *Obstet Gynecol* 2012;119:872]. *Obstet Gynecol* 2012;119:155–67. (Level III)
  16. Ueng J, Douketis JD. Prevention and treatment of hormone-associated venous thromboembolism: a patient management approach. *Hematol Oncol Clin North Am* 2010;24:683–94, vii–viii. (Level III)
  17. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arceus JJ, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published erratum appears in *Chest* 2012;141:1369]. *Chest* 2012;141:e227S–77S. (Level III)
  18. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. *Contraception* 2005;72:168–74. (Level II-1)
  19. Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD, et al. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. *J Clin Pharmacol* 2007;47:497–509. (Level II-3)
  20. Jick SS, Hagberg KW, Hernandez RK, Kaye JA. Post-marketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. *Contraception* 2010;81:16–21. (Level II-3)
  21. Raymond EG, Burke AE, Espey E. Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective. *Obstet Gynecol* 2012;119:1039–44. (Level III)
  22. Tepper NK, Dragoman MV, Gaffield ME, Curtis KM. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. *Contraception* 2017;95:130–9. (Systematic Review)
  23. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. *Am J Epidemiol* 1991;133:32–7. (Level II-3)
  24. Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. *N Engl J Med* 2012;366:2257–66. (Level II-3)
  25. Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17beta-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. *Contraception* 2013;87:706–27. (Level III)
  26. Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. *Contraception* 2016;94:328–39. (Level II-2)
  27. Petitti DB. Hormonal contraceptives and arterial thrombosis—not risk-free but safe enough. *N Engl J Med* 2012;366:2316–8. (Level III)
  28. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception. *Cochrane Database of Systematic Reviews* 2013, Issue 8. Art. No.: CD003989. (Systematic Review and Meta-Analysis)
  29. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. *Obstet Gynecol* 2007;110:587–93. (Level II-3)
  30. Dinger J, Mohner S, Heinemann K. Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. *Obstet Gynecol* 2013;122:800–8. (Level II-2)
  31. Dinger J, Bardenheuer K, Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. *Contraception* 2014;89:253–63. (Level II-2)
  32. Black A, Guilbert E, Costescu D, Dunn S, Fisher W, Kives S, et al. No. 329-Canadian Contraception Consensus Part 4 of 4 chapter 9: combined hormonal contraception. *J Obstet Gynaecol Can* 2017;39:268.e5. (Level III)
  33. U.S. Food and Drug Administration. FDA Drug Safety Communication: updated information about the risk of blood clots in women taking birth control pills containing drospirenone. Silver Spring (MD): FDA; 2012. (Level III)
  34. Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: a systematic review. *Contraception* 2016;94:678–700. (Systematic Review)
  35. Bergendal A, Odland V, Persson I, Kieler H. Limited knowledge on progestogen-only contraception and risk





- of venous thromboembolism. *Acta Obstet Gynecol Scand* 2009;88:261–6. (Meta-Analysis)
36. Bergendal A, Persson I, Odeberg J, Sundstrom A, Holmstrom M, Schulman S, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes [published erratum appears in *Obstet Gynecol* 2015;125:495]. *Obstet Gynecol* 2014;124:600–9. (Level II-2)
  37. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. *BMJ* 2012;345:e4944. (Systematic Review and Meta-Analysis)
  38. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. *Contraception* 1998;57:315–24. (Level II-2)
  39. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. *Arterioscler Thromb Vasc Biol* 2010;30:2297–300. (Level II-2)
  40. Kongsayreepong R, Chutivongse S, George P, Joyce S, McCone JM, Garza-Flores J, et al. A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. *Contraception* 1993;47:177–91. (Level II-2)
  41. Berenson AB, Rahman M, Wilkinson G. Effect of injectable and oral contraceptives on serum lipids. *Obstet Gynecol* 2009;114:786–94. (Level II-3)
  42. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandembroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. *Arch Intern Med* 2000;160:49–52. (Level II-2)
  43. Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. *Contraception* 2006;73:166–78. (Systematic Review)
  44. van Vlijmen EF, Brouwer JL, Veeger NJ, Eskes TK, de Graeff PA, van der Meer J. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. *Arch Intern Med* 2007;167:282–9. (Level II-3)
  45. Vandembroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. *Lancet* 1994;344:1453–7. (Level II-2)
  46. Spannagl M, Heinemann LA, Schramm W. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism? *Eur J Contracept Reprod Health Care* 2000;5:105–12. (Level II-2)
  47. Vandembroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? *BMJ* 1996;313:1127–30. (Level III)
  48. Comp PC. Thrombophilic mechanisms of OCs. *Int J Fertil Womens Med* 1997(suppl 1):170–6. (Level III)
  49. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. *Ann Intern Med* 1997;127:895–903. (Level III)
  50. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. *Thromb Haemost* 1998;80:874–7. (Meta-Analysis)
  51. Eichinger S. Homocysteine, vitamin B6 and the risk of recurrent venous thromboembolism. *Pathophysiol Haemost Thromb* 2003;33:342–4. (Level III)
  52. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. *J Thromb Haemost* 2005;3:292–9. (Meta-Analysis)
  53. Domagala TB, Adamek L, Nizankowska E, Sanak M, Szczeklik A. Mutations C677T and A1298C of the 5,10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease. *Blood Coagul Fibrinolysis* 2002;13:423–31. (Level II-2)
  54. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. *Medicine (Baltimore)* 2003;82:299–308. (Level II-3)
  55. Martinez-Berriotxo A, Ruiz-Irastorza G, Egurbide MV, Garmendia M, Gabriel Erdozain J, Villar I, et al. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. *Lupus* 2007;16:810–6. (Level II-3)
  56. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. *Arthritis Rheum* 2009;61:29–36. (Level II-3)
  57. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. *Am J Epidemiol* 1997;145:408–15. (Level II-3)
  58. Culwell KR, Navarro GM. Contraception for women with rheumatologic disease. In: Allen RH, Cwiak CA, editors. *Contraception for the medically challenging patient*. New York (NY): Springer; 2014. p. 307–20. (Level III)
  59. Choojitarom K, Verasertniyom O, Totemchokchayakarn K, Nantiruj K, Sumethkul V, Janwityanujit S. Lupus nephritis and Raynaud's phenomenon are significant risk





- factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. *Clin Rheumatol* 2008; 27:345–51. (Level II-3)
60. Wahl DG, Guillemain F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—a meta-analysis. *Lupus* 1997;6:467–73. (Systematic Review and Meta-Analysis)
  61. Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. *Obstet Gynecol* 2009;114:341–53. (Systematic Review)
  62. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, Mesanza-Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. *N Engl J Med* 2005;353:2539–49. (Level I)
  63. Curtis KM, Nanda K, Kapp N. Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review. *AIDS* 2009;23(suppl 1):S55–67. (Systematic Review)
  64. Paulen ME, Folger SG, Curtis KM, Jamieson DJ. Contraceptive use among solid organ transplant patients: a systematic review. *Contraception* 2010;82:102–12. (Systematic Review)
  65. Heikinheimo O, Lehtovirta P, Aho I, Ristola M, Paavonen J. The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study. *Am J Obstet Gynecol* 2011;204:126.e1–4. (Level II-2)
  66. Ramhendar T, Byrne P. Use of the levonorgestrel-releasing intrauterine system in renal transplant recipients: a retrospective case review. *Contraception* 2012;86:288–9. (Level III)
  67. Jackson E, Glasier A. Return of ovulation and menses in postpartum nonlactating women: a systematic review. *Obstet Gynecol* 2011;117:657–62. (Systematic Review)
  68. Tepper NK, Boulet SL, Whiteman MK, Monsour M, Marchbanks PA, Hooper WC, et al. Postpartum venous thromboembolism: incidence and risk factors. *Obstet Gynecol* 2014;123:987–96. (Level II-3)
  69. Jackson E, Curtis KM, Gaffield ME. Risk of venous thromboembolism during the postpartum period: a systematic review. *Obstet Gynecol* 2011;117:691–703. (Systematic Review)
  70. Petersen JF, Bergholt T, Nielsen AK, Paidas MJ, Lokkegaard EC. Combined hormonal contraception and risk of venous thromboembolism within the first year following pregnancy. Danish nationwide historical cohort 1995–2009. *Thromb Haemost* 2014;112:73–8. (Level II-3)
  71. Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MS. Risk of a thrombotic event after the 6-week postpartum period. *N Engl J Med* 2014;370:1307–15. (Level II-3)
  72. Sultan AA, Tata LJ, West J, Fiaschi L, Fleming KM, Nelson-Piercy C, et al. Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. *Blood* 2013;121:3953–61. (Level II-3)
  73. Sultan AA, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. *Br J Haematol* 2012;156:366–73. (Level II-3)
  74. Long-acting reversible contraception: implants and intrauterine devices. Practice Bulletin No. 186. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2017;130:e251–69. (Level III)
  75. Immediate postpartum long-acting reversible contraception. Committee Opinion No. 670. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2016; 128:e32–7. (Level III)
  76. Braga GC, Ferrioli E, Quintana SM, Ferriani RA, Pfrimer K, Vieira CS. Immediate postpartum initiation of etonogestrel-releasing implant: a randomized controlled trial on breastfeeding impact. *Contraception* 2015;92: 536–42. (Level I)
  77. American Academy of Pediatrics, American College of Obstetricians and Gynecologists. Contraception and the breastfeeding mother. In: *Breastfeeding handbook for physicians*. 2nd ed. Washington, DC: American College of Obstetricians and Gynecologists; Elk Grove Village (IL): AAP; 2014:193–7. (Level III)
  78. Lopez LM, Grey TW, Stuebe AM, Chen M, Truitt ST, Gallo MF. Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. *Cochrane Database of Systematic Reviews* 2015, Issue 3. Art. No.: CD003988. (Systematic Review and Meta-Analysis)
  79. Optimizing support for breastfeeding as part of obstetric practice. Committee Opinion No. 658. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2016; 127:e86–92. (Level III)
  80. Phillips SJ, Tepper NK, Kapp N, Nanda K, Temmerman M, Curtis KM. Progestogen-only contraceptive use among breastfeeding women: a systematic review. *Contraception* 2016;94:226–52. (Systematic Review)
  81. Tepper NK, Phillips SJ, Kapp N, Gaffield ME, Curtis KM. Combined hormonal contraceptive use among breastfeeding women: an updated systematic review. *Contraception* 2016;94:262–74. (Systematic Review)
  82. Leridon H. A new estimate of permanent sterility by age: sterility defined as the inability to conceive. *Popul Stud (Camb)* 2008;62:15–24. (Level III)
  83. Gambacciani M, Cappagli B, Lazzarini V, Ciaponi M, Fruzzetti F, Genazzani AR. Longitudinal evaluation of perimenopausal bone loss: effects of different low dose oral contraceptive preparations on bone mineral density. *Maturitas* 2006;54:176–80. (Level II-1)
  84. Davis A, Godwin A, Lippman J, Olson W, Kafrisen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. *Obstet Gynecol* 2000;96:913–20. (Level I)
  85. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. *Fertil Steril* 2001;75:1065–79. (Level I)



86. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hanford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. *Am J Obstet Gynecol* 2017;216:580.e1-9. (Level II-2)
87. Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Farmer RD. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. *Eur J Contracept Reprod Health Care* 2000;5:265-74. (Level II-3)
88. Management of abnormal uterine bleeding associated with ovulatory dysfunction. Practice Bulletin No. 136. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2013;122:176-85. (Level III)
89. Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. *Am J Obstet Gynecol* 2016;214:31-44. (Level III)
90. Dragoman MV, Simmons KB, Paulen ME, Curtis KM. Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review. *Contraception* 2017;95:117-29. (Systematic Review)
91. Lopez LM, Bernholc A, Chen M, Grey TW, Otterness C, Westhoff C, et al. Hormonal contraceptives for contraception in overweight or obese women. *Cochrane Database of Systematic Reviews* 2016, Issue 8. Art. No.: CD008452. (Systematic Review)
92. McNicholas C, Zhao Q, Secura G, Allsworth JE, Madden T, Peipert JF. Contraceptive failures in overweight and obese combined hormonal contraceptive users. *Obstet Gynecol* 2013;121:585-92. (Level II-2)
93. Simmons KB, Edelman AB. Hormonal contraception and obesity. *Fertil Steril* 2016;106:1282-8. (Level III)
94. Edelman AB, Carlson NE, Cherala G, Munar MY, Stouffer RL, Cameron JL, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. *Contraception* 2009;80:119-27. (Level II-2)
95. Edelman AB, Cherala G, Munar MY, Dubois B, McInnis M, Stanczyk FZ, et al. Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptive users. *Contraception* 2013;87:220-6. (Level III)
96. Edelman AB, Cherala G, Munar MY, McInnis M, Stanczyk FZ, Jensen JT. Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. *Contraception* 2014;90:550-6. (Level I)
97. Dinger J, Minh TD, Buttman N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. *Obstet Gynecol* 2011;117:33-40. (Level II-2)
98. Ziemann M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. *Fertil Steril* 2002;77:S13-8. (Level III)
99. Westhoff CL, Torgal AH, Mayeda ER, Petrie K, Thomas T, Dragoman M, et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women [published erratum appears in *Am J Obstet Gynecol* 2013;208:326]. *Am J Obstet Gynecol* 2012;207:39.e1-6. (Level II-3)
100. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. *Thromb Haemost* 2003;89:493-8. (Level II-2)
101. Trussell J, Guthrie KA, Schwarz EB. Much ado about little: obesity, combined hormonal contraceptive use and venous thrombosis. *Contraception* 2008;77:143-6. (Level III)
102. Larsen TB, Sorensen HT, Gislum M, Johnsen SP. Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: a population-based nested case-control study. *Thromb Res* 2007;120:505-9. (Level II-3)
103. Virkus RA, Lokkegaard E, Lidegaard O, Langhoff-Roos J, Nielsen AK, Rothman KJ, et al. Risk factors for venous thromboembolism in 1.3 million pregnancies: a nationwide prospective cohort. *PLoS One* 2014;9:e96495. (Level II-3)
104. Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use among obese women and risk for cardiovascular events: a systematic review. *Contraception* 2016;94:590-604. (Systematic Review)
105. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate and medroxyprogesterone acetate. 1. Use-effectiveness. *Contraception* 1977;15:513-33. (Level I)
106. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. *Contraception* 2004;70:269-75. (Level II-3)
107. Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. *Obstet Gynecol* 2012;120:21-6. (Level II-2)
108. Gerlach LS, Saldana SN, Wang Y, Nick TG, Spigarelli MG. Retrospective review of the relationship between weight change and demographic factors following initial depot medroxyprogesterone acetate injection in adolescents. *Clin Ther* 2011;33:182-7. (Level II-3)
109. Curtis KM, Ravi A, Gaffield ML. Progestogen-only contraceptive use in obese women. *Contraception* 2009;80:346-54. (Systematic Review)
110. Bonny AE, Ziegler J, Harvey R, Debanne SM, Secic M, Cromer BA. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. *Arch Pediatr Adolesc Med* 2006;160:40-5. (Level II-2)
111. Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. *J Pediatr Adolesc Gynecol* 2002;15:79-82. (Level II-3)
112. Lopez LM, Ramesh S, Chen M, Edelman A, Otterness C, Trussell J, et al. Progestin-only contraceptives: effects on



- weight. *Cochrane Database of Systematic Reviews* 2016, Issue 8. Art. No.: CD008815. (Systematic Review)
113. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. *Hum Reprod* 2013;28:2966–71. (Level II-3)
  114. Morelli M, Di Cello A, Venturella R, Mocciaro R, D'Alessandro P, Zullo F. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women. *Gynecol Endocrinol* 2013;29:156–9. (Level III)
  115. Paulen ME, Zapata LB, Cansino C, Curtis KM, Jamieson DJ. Contraceptive use among women with a history of bariatric surgery: a systematic review. *Contraception* 2010;82:86–94. (Systematic Review)
  116. Pagano HP, Zapata LB, Berry-Bibee EN, Nanda K, Curtis KM. Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review. *Contraception* 2016;94:641–9. (Systematic Review)
  117. Koke SC, Brown EB, Miner CM. Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. *Am J Obstet Gynecol* 2002;187:551–5. (Level II-3)
  118. Hall KS, Steinberg JR, Cwiak CA, Allen RH, Marcus SM. Contraception and mental health: a commentary on the evidence and principles for practice. *Am J Obstet Gynecol* 2015;212:740–6. (Level III)
  119. Berry-Bibee EN, Kim MJ, Simmons KB, Tepper NK, Riley HE, Pagano HP, et al. Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review. *Contraception* 2016;94:650–67. (Systematic Review)
  120. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. *Contraception* 2005;71:402–8. (Level II-3)
  121. Berry-Bibee EN, Kim MJ, Tepper NK, Riley HE, Curtis KM. Co-administration of St. John's wort and hormonal contraceptives: a systematic review. *Contraception* 2016;94:668–77. (Systematic Review)
  122. Tepper DE. Headache toolbox: menstrual migraine. *Headache* 2014;54:403–8. (Level III)
  123. The International Classification of Headache Disorders. 3rd ed. Headache Classification Committee of the International Headache Society (IHS) Cephalalgia; 2018;38:1–211. Retrieved August 27, 2018. (Level III)
  124. Tepper NK, Whiteman MK, Zapata LB, Marchbanks PA, Curtis KM. Safety of hormonal contraceptives among women with migraine: a systematic review. *Contraception* 2016;94:630–40. (Systematic Review)
  125. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. *JAMA* 2000;284:72–8. (Meta-Analysis)
  126. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. *BMJ* 2009;339:b3914. (Systematic Review and Meta-Analysis)
  127. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. *Am J Med* 2010;123:612–24. (Meta-Analysis)
  128. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council for High Blood Pressure Research. *Stroke* 2014;45:1545–88. (Level III)
  129. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies [published errata appear in *BMJ* 2005;330:596; *BMJ* 2005;330:345]. *BMJ* 2005;330:63. (Systematic Review and Meta-Analysis)
  130. Kurth T, Slomke MA, Kase CS, Cook NR, Lee IM, Gaziano JM, et al. Migraine, headache, and the risk of stroke in women: a prospective study. *Neurology* 2005;64:1020–6. (Level II-2)
  131. Carolei A, Marini C, De Matteis G. History of migraine and risk of cerebral ischaemia in young adults. The Italian National Research Council Study Group on Stroke in the Young. *Lancet* 1996;347:1503–6. (Level II-2)
  132. Sacco S, Merki-Feld GS, Aegidius KL, Bitzer J, Canonico M, Kurth T, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). *J Headache Pain* 2017;18:108. (Systematic Review)
  133. MacGregor EA. Migraine and use of combined hormonal contraceptives: a clinical review. *J Fam Plann Reprod Health Care* 2007;33:159–69. (Systematic Review)
  134. Champaloux SW, Tepper NK, Monsour M, Curtis KM, Whiteman MK, Marchbanks PA, et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. *Am J Obstet Gynecol* 2017;216:489.e1–7. (Level II-3)
  135. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published erratum appears in *J Am Coll Cardiol* 2018;71:2275-9]. *J Am Coll Cardiol* 2018;71:e127–248. (Level III)
  136. Curtis KM, Mohllajee AP, Martins SL, Peterson HB. Combined oral contraceptive use among women with hypertension: a systematic review. *Contraception* 2006;73:179–88. (Systematic Review)





137. Steenland MW, Zapata LB, Brahma D, Marchbanks PA, Curtis KM. Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review. *Contraception* 2013;87: 611–24. (Systematic Review)
138. Cardoso F, Polonia J, Santos A, Silva-Carvalho J, Ferreira-de-Almeida J. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. *Int J Gynaecol Obstet* 1997;59:237–43. (Level II-3)
139. Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, et al. U.S. selected practice recommendations for contraceptive use, 2016. *MMWR Recomm Rep* 2016;65(RR-4):1–66. (Level III)
140. Hussain SF. Progestogen-only pills and high blood pressure: is there an association? A literature review. *Contraception* 2004;69:89–97. (Level III)
141. Glisic M, Shahzad S, Tsoli S, Chadni M, Asllanaj E, Rojas LZ, et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis. *Eur J Prev Cardiol* 2018;25: 1042–52. (Systematic Review and Meta-Analysis)
142. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. *Cochrane Database of Systematic Reviews* 2014, Issue 4. Art. No.: CD006133. (Systematic Review and Meta-Analysis)
143. Visser J, Snel M, Van Vliet HA. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2. *Cochrane Database of Systematic Reviews* 2013, Issue 3. Art. No.: CD003990. (Systematic Review)
144. Diab KM, Zaki MM. Contraception in diabetic women: comparative metabolic study of Norplant, depot medroxyprogesterone acetate, low dose oral contraceptive pill and CuT380A. *J Obstet Gynaecol Res* 2000;26:17–26. (Level II-3)
145. Grabrick DM, Hartmann LC, Cerhan JR, Vierkant RA, Therneau TM, Vachon CM, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. *JAMA* 2000;284:1791–8. (Level II-2)
146. Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. *kConFab Investigators, Ontario Cancer Genetics Network Investigators. Cancer Epidemiol Biomarkers Prev* 2006; 15:1863–70. (Level II-2)
147. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Collaborative Group on Hormonal Factors in Breast Cancer. *Lancet* 2001;358:1389–99. (Level II-2)
148. Gaffield ME, Culwell KR, Ravi A. Oral contraceptives and family history of breast cancer. *Contraception* 2009; 80:372–80. (Systematic Review)
149. Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. *J Clin Oncol* 2013;31:4188–98. (Systematic Review and Meta-Analysis)
150. Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis [published erratum appears in *J Natl Cancer Inst* 2014;106:dju235]. *J Natl Cancer Inst* 2014;106:dju091. (Systematic Review and Meta-Analysis)
151. Management of gynecologic issues in women with breast cancer. Practice Bulletin No. 126. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2012; 119:666–82. (Level III)
152. Polin SA, Ascher SM. The effect of tamoxifen on the genital tract. *Cancer Imaging* 2008;8:135–45. (Level III)
153. Dominick S, Hickey M, Chin J, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. *Cochrane Database of Systematic Reviews* 2015, Issue 12. Art. No.: CD007245. (Systematic Review and Meta-Analysis)
154. Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. *Fertil Steril* 2008; 90:17–22. (Level II-2)
155. Stewart FH, Harper CC, Ellertson CE, Grimes DA, Sawaya GF, Trussell J. Clinical breast and pelvic examination requirements for hormonal contraception: current practice vs evidence. *JAMA* 2001;285:2232–9. (Level III)
156. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. *J Clin Oncol* 2007;25:2798–803. (Level II-3)
157. Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. *Am J Obstet Gynecol* 2015;213:469–78. (Systematic Review and Meta-Analysis)
158. Gaffield ME, Kapp N, Curtis KM. Combined oral contraceptive and intrauterine device use among women with gestational trophoblastic disease. *Contraception* 2009;80: 363–71. (Systematic Review)
159. Battino D, Tomson T, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. *EURAP Study Group. Epilepsia* 2013;54: 1621–7. (Level II-2)
160. Borthen I, Eide MG, Daltveit AK, Gilhus NE. Obstetric outcome in women with epilepsy: a hospital-based, retrospective study. *BJOG* 2011;118:956–65. (Level II-2)
161. Pennell PB. Pregnancy, epilepsy, and women's issues. *Continuum (Minneapolis Minn)* 2013;19:697–714. (Level III)
162. Gaffield ME, Culwell KR, Lee CR. The use of hormonal contraception among women taking anticonvulsant therapy. *Contraception* 2011;83:16–29. (Systematic Review)
163. Saano V, Glue P, Banfield CR, Reidenberg P, Colucci RD, Meehan JW, et al. Effects of felbamate on the phar-





- macokinetics of a low-dose combination oral contraceptive. *Clin Pharmacol Ther* 1995;58:523–31. (Level I)
164. Davis AR, Westhoff CL, Stanczyk FZ. Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. *Epilepsia* 2011;52:243–7. (Level II-3)
  165. Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, Orme M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. *Br J Clin Pharmacol* 1990;30:892–6. (Level II-3)
  166. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. *Epilepsia* 1997;38:317–23. (Level II-3)
  167. Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. *Epilepsia* 1999;40:783–7. (Level II-3)
  168. Davis AR, Pack AM, Dennis A. Contraception for women with epilepsy. In: Allen RH, Cwiak CA, editors. *Contraception for the medically challenging patient*. New York (NY): Springer; 2014:135–6. (Level III)
  169. Bounds W, Guillebaud J. Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs. *J Fam Plann Reprod Health Care* 2002;28:78–80. (Level III)
  170. Lazowitz A, Davis A, Swartz M, Guiahi M. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users. *Contraception* 2017;95:571–7. (Level III)
  171. Schindlbeck C, Janni W, Friese K. Failure of Implanon contraception in a patient taking carbamazepin for epilepsy. *Arch Gynecol Obstet* 2006;273:255–6.
  172. Lange J, Teal S, Tocce K. Decreased efficacy of an etonogestrel implant in a woman on antiepileptic medications: a case report. *J Med Case Rep* 2014;8:43.
  173. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. *Epilepsia* 2005;46:1414–7. (Level III)
  174. Christensen J, Petrenaite V, Atterman J, Sidenius P, Ohman I, Tomson T, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. *Epilepsia* 2007;48:484–9. (Level I)
  175. Back DJ, Breckenridge AM, Crawford F, MacIver M, Orme ML, Park BK, et al. The effect of rifampicin on norethisterone pharmacokinetics. *Eur J Clin Pharmacol* 1979;15:193–7. (Level III)
  176. Back DJ, Breckenridge AM, Crawford FE, Hall JM, MacIver M, Orme ML, et al. The effect of rifampicin on the pharmacokinetics of ethinylestradiol in women. *Contraception* 1980;21:135–43. (Level III)
  177. LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, et al. Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. *J Clin Pharmacol* 1998;38:1042–50. (Level II-3)
  178. Dickinson BD, Altman RD, Nielsen NH, Sterling ML. Drug interactions between oral contraceptives and antibiotics. Council on Scientific Affairs, American Medical Association. *Obstet Gynecol* 2001;98:853–60. (Level III)
  179. Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. *J Am Acad Dermatol* 2002;46:917–23. (Level III)
  180. Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review. *Am J Obstet Gynecol* 2018;218:88–97.e14. (Systematic Review)
  181. Hilbert J, Messig M, Kuye O, Friedman H. Evaluation of interaction between fluconazole and an oral contraceptive in healthy women. *Obstet Gynecol* 2001;98:218–23. (Level II-3)
  182. Verhoeven CH, van den Heuvel MW, Mulders TM, Dieben TO. The contraceptive vaginal ring, NuvaRing, and antimycotic co-medication. *Contraception* 2004;69:129–32. (Level II-1)
  183. Dogterom P, van den Heuvel MW, Thomsen T. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. *Clin Pharmacokinet* 2005;44:429–38. (Level II-1)
  184. Abrams LS, Skee D, Natarajan J, Wong FA. Pharmacokinetic overview of Ortho Evra/Evra. *Fertil Steril* 2002;77:S3–12. (Level III)
  185. World Health Organization. *Injectable contraceptives: their role in family planning care*. Geneva: WHO; 1990. (Level III)
  186. Culwell KR, Curtis KM. Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy: a systematic review. *Contraception* 2009;80:337–45. (Systematic Review)
  187. Sonmezer M, Atabekoglu C, Cengiz B, Dokmeci F, Cengiz SD. Depot-medroxyprogesterone acetate in anticoagulated patients with previous hemorrhagic corpus luteum. *Eur J Contracept Reprod Health Care* 2005;10:9–14. (Level III)
  188. Schaedel ZE, Dolan G, Powell MC. The use of the levonorgestrel-releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders. *Am J Obstet Gynecol* 2005;193:1361–3. (Level II-2)
  189. Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ. Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). *Lupus* 2006;15:877–80. (Level III)
  190. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. *Obstet Gynecol* 2011;117:777–87. (Level I)
  191. Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. *Blood* 2016;127:1417–25. (Level I)



Published online on January 24, 2019.

The MEDLINE database, the Cochrane Library, and the American College of Obstetricians and Gynecologists' own internal resources and documents were used to conduct a literature search to locate relevant articles published between January 2000–July 2018. The search was restricted to articles published in the English language. Priority was given to articles reporting results of original research, although review articles and commentaries also were consulted. Abstracts of research presented at symposia and scientific conferences were not considered adequate for inclusion in this document. Guidelines published by organizations or institutions such as the National Institutes of Health and the American College of Obstetricians and Gynecologists were reviewed, and additional studies were located by reviewing bibliographies of identified articles. When reliable research was not available, expert opinions from obstetrician–gynecologists were used.

Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force:

- I Evidence obtained from at least one properly designed randomized controlled trial.
- II-1 Evidence obtained from well-designed controlled trials without randomization.
- II-2 Evidence obtained from well-designed cohort or case–control analytic studies, preferably from more than one center or research group.
- II-3 Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.
- III Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

Based on the highest level of evidence found in the data, recommendations are provided and graded according to the following categories:

Level A—Recommendations are based on good and consistent scientific evidence.

Level B—Recommendations are based on limited or inconsistent scientific evidence.

Level C—Recommendations are based primarily on consensus and expert opinion.

Copyright 2019 by the American College of Obstetricians and Gynecologists. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, posted on the Internet, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the publisher.

Requests for authorization to make photocopies should be directed to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400.

**American College of Obstetricians and Gynecologists**  
**409 12th Street, SW, PO Box 96920, Washington, DC 20090-6920**

Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 206. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2019;133:e128–50.



---

*This information is designed as an educational resource to aid clinicians in providing obstetric and gynecologic care, and use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgment of the treating clinician. Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The American College of Obstetricians and Gynecologists reviews its publications regularly; however, its publications may not reflect the most recent evidence. Any updates to this document can be found on [www.acog.org](http://www.acog.org) or by calling the ACOG Resource Center.*

*While ACOG makes every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. ACOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither ACOG nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.*

*All ACOG committee members and authors have submitted a conflict of interest disclosure statement related to this published product. Any potential conflicts have been considered and managed in accordance with ACOG’s Conflict of Interest Disclosure Policy. The ACOG policies can be found on [acog.org](http://acog.org). For products jointly developed with other organizations, conflict of interest disclosures by representatives of the other organizations are addressed by those organizations. The American College of Obstetricians and Gynecologists has neither solicited nor accepted any commercial involvement in the development of the content of this published product.*

